Division of Clinical, Social and Administrative Sciences

Faculty

Thomas L Rihn, Pharm.D. Associate Dean, Research and Graduate Programs Noble J. Dick Endowed Chair in Academic Leadership Associate Professor of Pharmaceutics 312 Bayer T 412.396.1295 rihn@duq.edu

Educational Background

B.S. (Pharmacy)--Duquesne University
Pharm.D. -- Duquesne University

Select Publications

• Rihn TL, Diez J, and The Heparin Consensus Group.  Unfractionated Heparin in Cardiology: Redefining the Standard of Practice.  Pharmacotherapy August 2004.
• Dobesh P, Rihn TL and The Heparin Consensus Group.  Nomograms: Roadmaps to Where?  Pharmacotherapy August 2004.
• Niccolai CS, Hicks RW, Oertel L, Francis J, Rihn TL and The Heparin Consensus Group.  UFH: Focus on a “High-Alert” Medication.  Pharmacotherapy August 2004.
• Dobesh P, Rihn TL and T he Heparin Consensus Group.  Economics of UFH: Beyond Acquisition of Cost.  Pharmacotherapy August 2004.
• Rihn TL, Unfractionated Heparin in Cardiology:  Redefining the Standard of Practice.  Pharmacotherapy 2004;24:132S-141S.
• Rihn TL, Vanscoy GJ, O’Neill C. “Optimizing Erythropoietic Growth Factor Management: Interchange Opportunities”. Formulary. 2005;20:1-16 (Suppl Dec 2005).
• Vanscoy GJ, Rihn TL. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics.  Community Oncology 2005;2:127-132.
• Rihn TL, Vanscoy GJ, Koerner P.  Optimizing erythropoietic growth factor formulary management: interchange opportunities.  Formulary 2005;40:1-12 (suppl Dec).
• Rihn, TL, Book Chapter, Clinical Significance , Foye’s Principles ofMedicinal Chemistry, July 2007.

Select Presentations

• Cancer Support Innovation:  Economic Considerations, Annual American College of Clinical Pharmacy, Dallas, Texas, October 2004.
• Contemporary Anticoagulant Therapy: A Focus on Special Populations, 40th ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 2005.
• Optimizing Erythropoietic Growth Factor Formulary Management, Virginia Society of Health- System Pharmacists, Harrisonburg, Virginia.  June 2005.
• Update on VTE Management: Challenging the Heparin Paradigm, Pennsylvania North Central Society of Health-System Pharmacists, Dubois, Pennsylvania.  September 2005.
• Update on VTE Management: Challenging the Heparin Paradigm, Ohio Society of Health-System Pharmacists, Cleveland, Ohio.  September 2005.
• Expanding the Pharmacist’s Role in Anemia and Neutropenia Management, National Scientific Education Panel, Phoenix, Arizona.  September 2005.
• Evaluating Fibrinolytic Use Across Indications, Kentucky Society of Health-System Pharmacists, Louisville, Kentucky.  September 2005.
• Concisely Evaluating a Formulary Class Across Indications: The New Fibrinolytic Model, Michigan Society of Health-System Pharmacists, Grand Rapids, Michigan.  January 2006.
• Recent Advances in the Management of Acute Decompensated Heart Failure, Texas Society of Health System Pharmacists, Houston, Texas.  March 2006
• Optimizing the Prophylaxis and Treatment of VTE: Enhancing Awareness, Management, and Quality.  Trinity Health System, Steubenville, Ohio.  May 2007.
• Enhancing Erythropoietic Stimulating Protein Management: Charting Recent Advances, Georgia Society of Health-System Pharmacists, Columbus, Georgia.  May 2007.
• A Primer on Antithrombotic Therapy in Venous Thromboembolism, A web-based CPE program (UPA-LLC.com), May 2007.
• A Primer on Antithrombotic Therapy in Acute Coronary Syndromes, A web-based CPE program (UPA-LLC.com), May 2007.
• Evolving Concepts on Anticoagulant Therapy in ACS, New York City Society of Health-System Pharmacists, January 2008.